CYCN
Price
$1.53
Change
+$0.06 (+4.08%)
Updated
Nov 26, 04:38 PM (EDT)
Capitalization
5.79M
Intraday BUY SELL Signals
GRCE
Price
$3.20
Change
-$0.00 (-0.00%)
Updated
Nov 26, 04:59 PM (EDT)
Capitalization
49.67M
Intraday BUY SELL Signals
Interact to see
Advertisement

CYCN vs GRCE

Header iconCYCN vs GRCE Comparison
Open Charts CYCN vs GRCEBanner chart's image
Cyclerion Therapeutics
Price$1.53
Change+$0.06 (+4.08%)
Volume$516
Capitalization5.79M
Grace Therapeutics
Price$3.20
Change-$0.00 (-0.00%)
Volume$200
Capitalization49.67M
CYCN vs GRCE Comparison Chart in %
CYCN
Daily Signal:
Gain/Loss:
GRCE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CYCN vs. GRCE commentary
Nov 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYCN is a Hold and GRCE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 27, 2025
Stock price -- (CYCN: $1.47 vs. GRCE: $3.20)
Brand notoriety: CYCN and GRCE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYCN: 6% vs. GRCE: 78%
Market capitalization -- CYCN: $5.6M vs. GRCE: $49.52M
CYCN [@Biotechnology] is valued at $5.6M. GRCE’s [@Biotechnology] market capitalization is $49.52M. The market cap for tickers in the [@Biotechnology] industry ranges from $109.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYCN’s FA Score shows that 1 FA rating(s) are green whileGRCE’s FA Score has 0 green FA rating(s).

  • CYCN’s FA Score: 1 green, 4 red.
  • GRCE’s FA Score: 0 green, 5 red.
According to our system of comparison, GRCE is a better buy in the long-term than CYCN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYCN’s TA Score shows that 5 TA indicator(s) are bullish while GRCE’s TA Score has 6 bullish TA indicator(s).

  • CYCN’s TA Score: 5 bullish, 2 bearish.
  • GRCE’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, both CYCN and GRCE are a good buy in the short-term.

Price Growth

CYCN (@Biotechnology) experienced а +3.52% price change this week, while GRCE (@Biotechnology) price change was +1.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.60%. For the same industry, the average monthly price growth was -1.29%, and the average quarterly price growth was +72.73%.

Industries' Descriptions

@Biotechnology (+4.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GRCE($49.7M) has a higher market cap than CYCN($5.79M). GRCE YTD gains are higher at: -14.439 vs. CYCN (-54.348). CYCN has higher annual earnings (EBITDA): -3.76M vs. GRCE (-14.8M). GRCE has more cash in the bank: 20M vs. CYCN (3.01M). CYCN has higher revenues than GRCE: CYCN (2.17M) vs GRCE (0).
CYCNGRCECYCN / GRCE
Capitalization5.79M49.7M12%
EBITDA-3.76M-14.8M25%
Gain YTD-54.348-14.439376%
P/E RatioN/AN/A-
Revenue2.17M0-
Total Cash3.01M20M15%
Total Debt0N/A-
FUNDAMENTALS RATINGS
CYCN vs GRCE: Fundamental Ratings
CYCN
GRCE
OUTLOOK RATING
1..100
307
VALUATION
overvalued / fair valued / undervalued
1..100
10
Undervalued
44
Fair valued
PROFIT vs RISK RATING
1..100
10042
SMR RATING
1..100
9291
PRICE GROWTH RATING
1..100
6557
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYCN's Valuation (10) in the null industry is somewhat better than the same rating for GRCE (44) in the Pharmaceuticals Other industry. This means that CYCN’s stock grew somewhat faster than GRCE’s over the last 12 months.

GRCE's Profit vs Risk Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for CYCN (100) in the null industry. This means that GRCE’s stock grew somewhat faster than CYCN’s over the last 12 months.

GRCE's SMR Rating (91) in the Pharmaceuticals Other industry is in the same range as CYCN (92) in the null industry. This means that GRCE’s stock grew similarly to CYCN’s over the last 12 months.

GRCE's Price Growth Rating (57) in the Pharmaceuticals Other industry is in the same range as CYCN (65) in the null industry. This means that GRCE’s stock grew similarly to CYCN’s over the last 12 months.

GRCE's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as CYCN (100) in the null industry. This means that GRCE’s stock grew similarly to CYCN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYCNGRCE
RSI
ODDS (%)
Bullish Trend 2 days ago
87%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
74%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 6 days ago
79%
Declines
ODDS (%)
Bearish Trend 15 days ago
89%
Bearish Trend 10 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CYCN
Daily Signal:
Gain/Loss:
GRCE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MYNZ1.000.04
+3.99%
Mainz Biomed N.V.
FLL2.650.07
+2.71%
Full House Resorts
DKL45.820.89
+1.98%
Delek Logistics Partners LP
MAA135.061.75
+1.31%
Mid-America Apartment Communities
KOS1.09-0.05
-4.39%
Kosmos Energy Ltd

CYCN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCN has been loosely correlated with HRTX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCN jumps, then HRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCN
1D Price
Change %
CYCN100%
-1.34%
HRTX - CYCN
41%
Loosely correlated
-3.54%
GDTC - CYCN
30%
Poorly correlated
-0.52%
FATE - CYCN
29%
Poorly correlated
-2.78%
GRCE - CYCN
28%
Poorly correlated
+2.89%
IBIO - CYCN
25%
Poorly correlated
+5.41%
More

GRCE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRCE has been loosely correlated with SLNO. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GRCE jumps, then SLNO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRCE
1D Price
Change %
GRCE100%
+2.89%
SLNO - GRCE
38%
Loosely correlated
+8.41%
CYTK - GRCE
36%
Loosely correlated
+0.51%
ACOG - GRCE
32%
Poorly correlated
+1.25%
SCNI - GRCE
31%
Poorly correlated
+3.23%
LTRN - GRCE
31%
Poorly correlated
+13.65%
More